Ireland adds new vaccines to paediatric immunisation programme
This article was originally published in Scrip
Executive Summary
Ireland's Immunisation Guidelines 2008 has added two new vaccines to the primary childhood immunisation programme, and modified the timing of two other innoculations.Pneumococcal conjugate vaccine (PCV) will be added to the programme, along with the addition of a hepatitis B vaccine to the 5 in 1 vaccine, which currently protects against diphtheria, tetanus, whooping cough, Hib and polio. Changes in the timing of administration of the meningococcal C and Haemophilus (Hib) vaccines have also been made, reflecting recommendations for their inclusion in primary immunisation schedules at three to four months. The programme, produced by the National Immunisation Advisory Committee (NIAC) of the Royal College of Physicians of Ireland, serves to update the previous 2002 guidelines and help Ireland achieve its childhood immunisation goal of 95% uptake. Children are immunised free of charge under the programme.
You may also be interested in...
How to leverage India: Five up-and-coming domestic players
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
Active Biotech appoints CSO
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed appoints new chief commercial officer
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).